Identifying Predictors of Anti-VEGF Treatment Response in Patients with Neovascular Age-Related Macular Degeneration through Discriminant and Principal Component Analysis

被引:5
|
作者
Holz, Frank G. [1 ]
Tadayoni, Ramin [3 ]
Beatty, Stephen [4 ]
Berger, Alan R. [5 ,6 ]
Cereda, Matteo G. [7 ]
Hykin, Philip [8 ]
Hoyng, Carel B. [10 ]
Wittrup-Jensen, Kim [2 ]
Altemark, Andreas [2 ]
Nilsson, Jonas [11 ]
Kim, Kun [12 ]
Sivaprasad, Sobha [8 ,9 ]
机构
[1] Univ Bonn, Dept Ophthalmol, Bonn, Germany
[2] Bayer Pharmaceut, Berlin, Germany
[3] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France
[4] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland
[5] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada
[6] St Michaels Hosp, Toronto, ON, Canada
[7] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy
[8] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England
[9] Kings Coll Hosp London, Dept Ophthalmol, London, England
[10] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands
[11] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden
[12] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden
关键词
AURA; Intravitreal ranibizumab; Neovascular age-related macular degeneration; INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD;
D O I
10.1159/000449001
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:49 / 55
页数:7
相关论文
共 50 条
  • [1] Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
    Finger, Robert P.
    Wickremasinghe, Sanjeewa S.
    Baird, Paul N.
    Guymer, Robyn H.
    SURVEY OF OPHTHALMOLOGY, 2014, 59 (01) : 1 - 18
  • [2] Genetic Association Analysis of Anti-VEGF Treatment Response in Neovascular Age-Related Macular Degeneration
    Strunz, Tobias
    Poellmann, Michael
    Gamulescu, Maria-Andreea
    Tamm, Svenja
    Weber, Bernhard H. F.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (11)
  • [3] ANTI-VEGF TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN AUSTRALIA
    Finger, Robert
    Fotis, Kathy
    Cummins, Rob
    Heraghty, Julie
    Guymer, Robyn
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2014, 42 : 14 - 14
  • [4] Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration
    Wykoff, Charles C.
    Clark, W. Lloyd
    Nielsen, Jared S.
    Brill, Joel V.
    Greene, Laurence S.
    Heggen, Cherilyn L.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (02): : S3 - S15
  • [5] Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration
    Fauser, Sascha
    Lambrou, George N.
    SURVEY OF OPHTHALMOLOGY, 2015, 60 (02) : 138 - 152
  • [6] Neovascular age-related macular degeneration and anti-VEGF nonresponders
    Sheybani, Arsham
    Almony, Arghavan
    Blinder, Kevin J.
    Shah, Gaurav K.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2010, 5 (01) : 35 - 41
  • [7] Switching intravitreal anti-VEGF treatment in neovascular age-related macular degeneration
    Kucukerdonmez, Cem
    Gelisken, Faik
    Yoeruek, Efdal
    Bartz-Schmidt, Karl Ulrich
    Leitritz, Martin Alexander
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2015, 25 (01) : 51 - 56
  • [8] Patterns of response to Anti-VEGF treatment in a large urban cohort of patients with neovascular age-related macular degeneration
    Kanesa-thasan, Aditya
    Mirza, Rukhsana
    Lyon, Alice T.
    Gill, Manjot
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [9] Fibrosis in age-related neovascular macular degeneration in the anti-VEGF era
    Armendariz, Beatriz G.
    Chakravarthy, Usha
    EYE, 2024, : 3243 - 3251
  • [10] Volumetric fluid analysis of fixed monthly anti-VEGF treatment in patients with neovascular age-related macular degeneration
    Kim, Bo Hee
    Chang, In Boem
    Yu, Hyeong Gon
    Hong, In Hwan
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2023, 16 (06) : 909 - 914